Overview

CPG 7909 Injection in Melanoma

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To determine the safety, tolerability and effects of CPG 7909 (the study drug) when given with chemotherapy to patients with melanoma.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Dacarbazine